Antibody–drug conjugates (ADCs) are powerful, but also complex. How do antibody, linker and payload influence drug exposure, efficacy and safety? Join experts Kati Rasanen, Quigyu Cui and Tuomas Tervahauta to unpack this question and understand how to design smarter DMPK strategies to tackle ADC challenges and turn that complexity into clarity!
We present practical workflows, real-world examples and give you the tools you need to make early, informed decisions about DMPK in your ADC projects.
By attending this webinar, you will learn about:
- ADC fundamentals: Explore antibody, linker, and payload roles and how they influence PK and stability
- Mastering detection strategies: Find out which assays (LBA vs LC–MS/hybrid) to use for intact ADC, total antibody, free payload, and metabolite formation/identification
- How to address critical DMPK challenges such as: DAR distribution, linker stability, payload exposure, and immunogenicity considerations
- Apply PK/PD principles for decision-making: Design studies that link exposure to effect and set transparent go/no-go criteria early
